# PINNACLE<sup>21</sup>

## CDISC ANALYSIS RESULTS STANDARD

Jeff Abolafia - Director of Product Innovation





### JEFF ABOLAFIA

#### DIRECTOR OF PRODUCT INNOVATION

- ► 50% at FDA > RWE and Analysis Projects
- ► CDISC ADAM Team 15+ years
- CDISC Analysis Results Team
- ► CDISC E-2C Team
- PhUSE Real World Evidence Team
- ► PhUSE Research on FHIR Team



#### AGENDA

Background

What We Have Accomplished

What's Next


Q&A

THANK YOU!







#### **Analysis Results Current State**



**ADaM Dataset** 





ARM for define.xml



#### ANALYSIS RESULTS CURRENT STATE

- Static results created for Clinical Study Report
- May be hundred of tables in PDF format, often difficult to navigate
- No or limited traceability (e.g., to protocol, SAP, ADaM data)
- Expensive to generate and only used once, no or limited reusability

- ARM v1.0 describes metadata about displays (PDF) and results (at high level), no formal analysis and results model or results data.
- Lack of features to drive automation
- Limited regulatory use cases

## CDISC ANALYSIS RESULTS STANDARD SHIFTING THE PARADIGM


Table 3.1.1: ADHYPO Analysis Dataset												
Row	v STUDYID USUBJID		MIDS	CEDECOD	WASAEYN	ASTDTM						
1	XYZ	000001	НҮРО 1	Hypoglycemia	Y	07Sep2012 22:29:00						
2	XYZ	000001	НҮРО 2	Hypoglycemia	N	10Sep2012 09:12:00						
3	XYZ	000001	НҮРО 3	Hypoglycemia	N	10Sep2012 23:05:00						
4	XYZ	000001	НҮРО 4	Hypoglycemia	N	11Sep2012 15:24:00						
5	XYZ	000001	НҮРО 5	Hypoglycemia	N	18Sep2012 11:39:00						
6	XYZ	000002	НҮРО 1	Hypoglycemia	N	22Oct2012 13:28:00						
7	XYZ	000002	НҮРО 2	Hypoglycemia	N	25Oct2012 13:59:00						
8	XYZ	000002	НҮРО 3	Hypoglycemia	N	17Nov2012 05:01:00						



Metadata Field	Metadata	
DISPLAY IDENTIFIER	Table 4.2.1/Figure 4.2.1	
DISPLAY NAME	Mean Change from Baseline in HbA1c (Percent) Lor	ngitudinal Repeated Measures Ana
	Period, Intention-to-treat Population	
RESULT IDENTIFIER	Treatment difference results (LSMean, confidence in	iterval, p-value)
PARAM	HbA1c (%)	
PARAMCD	HBA1C	
ANALYSIS VARIABLE	CHG (Change from baseline)	
ANALYSIS REASON	SPECIFIED IN SAP	4514
ANALYSIS PURPOSE	PRIMARY OUTCOME MEASURE	ARM v1
ANALYSIS DATASET	ADHBA1C	

**ARM Extensions** 


#### **ADaM Dataset**







Reuse



**Analysis Results Dataset** 

Display Traceability

#### ANALYSIS RESULTS DESIRED FUTURE STATE

- Formal model for describing analyses and results as data
- Facilitate automated generation of results
- From electronic (PDF) to machine readable results, with context and metadata to source
- Improved navigation and reusability of analyses and results

- Support storage, access, processing and reproducibility of results
- Traceability to Protocol/SAP and to input ADaM data
- Open-source tools to design, specify, build and generate analysis results



#### ANALYSIS RESULTS STANDARDS GOALS



Formal model that describes analysis results metadata



Analysis Results Metadata Technical Specification (ARM-TS), to support automation, traceability, and creation of data displays



Define an Analysis Results Data (ARD) structure, to support reuse and reproducibility of results data



Illustrate and exercise ARD and ARM-TS with a set of machine-readable common safety displays


#### LIST OF INITIAL WORKING DATA DISPLAYS, CONCEPTS

Analysis Populations and Subject Disposition
Protocol Deviations
Demographics and Other Baseline Characteristics
Medical History
Prior and Concomitant Medications
Subject Incidence of Adverse Events
Treatment Emergent Adverse Events by SOC and PT
TEAE SOC and PT by Maximum Severity
Laboratory Tests by Visit
Change in Vital Signs by Visit


**P2**1


#### **EXTEND ARM**

- Prospective focus on automation, traceability, and creation of data displays
- Linked, modular, flexible and tool agnostics
- Supports meta-programming
- Serves a different purpose than ARM for Define-XML



# **CDISC 360: Extended Analysis Results Metadata Sample**





# **Draft Analysis Results Dataset Specification (ARDS) Metadata Describing the ARDS**

#### Analysis Results Dataset Specification - One record per result

Variable Name	Variable Label	Туре	Code list/ Controlled Terms	Core	CDISC Notes
STUDYID	Study Identifier	С			Unique identifier for a study
RESULTID	Result Identifier	С			Unique identifier for a result
TABLEID	Display Identifier	С			Sponsor defined identifier to tie a group of related results together
ADSNS	Source Datasets	С			List of source datasets separated by commas (i.e., ADSL, ADAE)
POPULATION	Analysis Population	С			Description of population (i.e., Safety Population)
TIME	Description of Time Frame	С			Time frame used in analysis (i.e., Visit 1 or 12 weeks)
WHERE	Description of Subsetting Criteria	С			selection criterion needed to select the required subset of records from the specified analysis dataset
BYVARz	Name of BYVARZ	С			The lower-case letter "z" in the variable name is the zth By-Variable, where "z" is replaced with a one-digit integer between 1 and 9.
BYVALz	Value of BYVARZ				The lower-case letter "z" in the variable name is the zth By-Variable, where "z" is replaced with a one-digit integer between 1 and 9.
TRTVAR	Treatment variable name	С			Name of treatment variable used in analysis (i.e. TRTP, TRT01P)
TRTVAL	Treatment value	С			Value of TRTVAR for a given record

	PARAMCD	Analysis Parameter	С		The description of the analysis parameter (i.e., Supine Systolic Blood Pressure (mm Hg)). Typically, only used with BDS datasets.
	ANAL_VAR	Analysis Variable	С		Analysis variable needed to create the respective analysis result.
	AVAR_VAL	Analysis Variable Value	С		Value of analysis. Typically, only used for categorical variables
	STATNAME	Name of Statistic	С		
	STATVAL	Value of Statistic	Float		
	STATDESC	Description of Statistic	С		
iŧ					

#### **Analysis Result Dataset: OCCDS Structure Example**

Protocol: CDISCPILOT01 Page 1 of 16
Population: Safety

Table 14-5.01
Incidence of Treatment Emergent Adverse Events by Treatment Group

	Placeb (N=86)		Xanomeline (N=84)		Xanomeline Hig (N=84)		Fisher's Exact p-values Placebo Placebo		
System Organ Class/	(0.)	f	(0.)	· ·	(0)	vs.	vs.		
Preferred Term	n (%)	[AEs]	n(%)	[AEs]	n(%) [A	Es] Low Dose	High Dose		
ANY BODY SYSTEM	65 (75.6%)	[281]	77 (91.7%)	[412]	76 (90.5%) [43	3] 0.007*	0.014*		
CARDIAC DISORDERS	12 (14.0%)	[26]	13 (15.5%)	[30]	15 (17.9%) [30	0.831	0.534		
SINUS BRADYCARDIA	2 ( 2.3%)	[2]	7 ( 8.3%)	[10]	8 ( 9.5%) [12]	0.097*	0.056*		
MYOCARDIAL INFARCTION	4 ( 4.7%)	[4]	2 ( 2.4%)	[4]	4 ( 4.8%) [8]	0.682	>0.99		
ATRIAL FIBRILLATION	1 ( 1.2%)	[1]	1 ( 1.2%)	[1]	3 ( 3.6%) [5]	>0.99	0.365		
ATRIAL FLUTTER	0		1 ( 1.2%)	[1]	1 ( 1.2%) [2]	0.494	0.494		
CARDIAC DISORDER	0		0		1 ( 1.2%) [1]		0.494		
SUPRAVENTRICULAR	1 ( 1.2%)	[2]	1 ( 1.2%)	[2]	1 ( 1.2%) [1]	>0.99	>0.99		
EXTRASYSTOLES									
VENTRICULAR EXTRASYSTOLES	0		2 ( 2.4%)	[4]	1 ( 1.2%) [1]	0.243	0.494		
ATRIAL HYPERTROPHY	1 ( 1.2%)	[2]	0		0	>0.99	>0.99		
ATRIOVENTRICULAR BLOCK	1 ( 1.2%)	[1]	1 ( 1.2%)	[1]	0	>0.99	>0.99		
FIRST DEGREE									
ATRIOVENTRICULAR BLOCK	1 ( 1.2%)	[1]	0		0	>0.99	>0.99		
SECOND DEGREE									
BRADYCARDIA	1 ( 1.2%)	[4]	0		0	>0.99	>0.99		
BUNDLE BRANCH BLOCK LEFT	1 ( 1.2%)		0		0	>0.99	>0.99		
BUNDLE BRANCH BLOCK RIGHT	1 ( 1.2%)	[2]	1 ( 1.2%)	[1]	0	>0.99	>0.99		

#### **Analysis Result Dataset: OCCDS Structure Example**

IDENTIFIERS DATA / POPULATION		LATION	BY VARIABLES							ANALYSIS VARIABLES				STATISTICS				
StudytID	ResultID	TableID	ADSNs	Population	Where	Time	ByVar1	ByVal1	ByVar2	ByVal2	TrtVar	TrtVal	ParamCD	Anal_Var	Anal_Var_Val	Stat_Name	Stat_Val	Stat_Desc
																		# subjects with
1234	AE01a1	AE01a	ADAE, ADSI	Safety							TRTP	D1		AE Incidence		N	XX	event
1234	AE01a2	AE01a	ADAE, ADSI	Safety							TRTP	P1		AE Incidence		N	XX	
																		% of subjects in
																		treatment grou
1234	AE01a3	AE01a	ADAE, ADSI	Safety							TRTP	D1		AE Incidence		Percent	XX.XX	with event
1234	AE01a4	AE01a	ADAE, ADSI	Safety							TRTP	P1		AE Incidence		Percent	XX.XX	
								Blood and										
								lymphatic										
								system										# subjects with
1234	AE01a5	AE01a	ADAE, ADSI	Safety			Body System	disorders			TRTP	D1		AE Incidence		N	XX	event
								Blood and										
								lymphatic										
								system										
1234	AE01a6	AE01a	ADAE, ADSI	Safety			Body System	disorders			TRTP	P1		AE Incidence		N	XX	
								Blood and										
								lymphatic										% of subjects i
								system										treatment grou
1234	AE01a7	AE01a	ADAE, ADSI	Safety			Body System	disorders			TRTP	D1		AE Incidence		Percent	XX.XX	with event
								Blood and										
								lymphatic										
								system										
1234	AE01a8	AE01a	ADAE, ADSI	Safety			Body System	disorders			TRTP	P1		AE Incidence		Percent	XX.XX	
								Blood and										
								lymphatic										
								system										# subjects with
1234	AE01a9	AE01a	ADAE, ADSI	Safety			Body System		PT	Anaemia	TRTP	D1		AE Incidence		N	XX	event
								Blood and										
								lymphatic										
								system										
1234	AE01a10	AE01a	ADAE, ADSI	Safety			Body System		PT	Anaemia	TRTP	P1		AE Incidence		N	XX	
								Blood and										
								lymphatic										% of subjects in
								system										treatment grou
1234	AE01a11	AE01a	ADAE, ADSI	Safety			Body System		PT	Anaemia	TRTP	D1		AE Incidence		Percent	XX.XX	with event
								Blood and										
								lymphatic										
								system										
1234	AE01a12	AE01a	ADAE, ADSI	Safety			Body System	disorders	PT	Anaemia	TRTP	P1		AE Incidence		Percent	XX.XX	



P21

WHAT'S NEXT

#### FUTURE DELIVERABLES

Formal model/technical specification that describes analysis results metadata


Analysis Results Dataset Specification

New Model and Implementation Guide to represent analysis results

**Terminology** 

Identification of Conformance Rules

## FUTURE DELIVERABLES: SUPPORT NEW FDA GUIDANCE "FDA STANDARD SAFETY TABLES AND FIGURES INTEGRATED GUIDE"



Make packages freely available on the CDISC website





# KEEP IN TOUCH!





